A Phase 3 interventional study of Levetiracetam and Carbamazepine Controlled Release (CBZ-CR) in Epilepsy, sponsored by UCB Pharma. Completed at 231 sites in 24 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-03-17.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one has the largest enrollment, is one of 5 that started in 2005, is one of 28 in phase 3, and was the 10th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,701 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one has the largest enrollment of the 116 interventional ones that give a count, is one of 8 that started in 2005, is one of 74 in phase 3, and was the 14th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study N01175 was to compare overall effectiveness (efficacy and safety) of levetiracetam (LEV) versus the 2 older antiepileptic drugs (AEDs), sodium valproate extended release (VPA-ER) and carbamazepine controlled release (CBZ-CR) in the treatment of subjects with newly diagnosed epilepsy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
Drug: Levetiracetam
Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
Drug: Carbamazepine Controlled Release (CBZ-CR) · Drug: Valproate Extended Release
Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
Time to withdrawal from study medication (starting at V1) as a measure of combined efficacy and safety
Time frame: Visit 1 to End of Study (approximately 52 weeks)
The time to withdrawal comparing Levetiracetam versus the older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release
Time frame: Visit 1 to End of Study (approximately 52 weeks)
The retention rate after 6 months comparing Levetiracetam versus the older Antiepileptic Drugs
Time frame: Visit 1 to Visit 4 (approximately 26 weeks)
The retention rate after 12 months comparing Levetiracetam versus the older Antiepileptic Drugs
Time frame: Visit 1 to Visit 5 (approximately 52 weeks)
The retention rate after 6 months comparing Levetiracetam versus older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release
Time frame: Visit 1 to Visit 4 (approximately 26 weeks)
The retention rate after 12 months comparing Levetiracetam versus older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release
Time frame: Visit 1 to Visit 5 (approximately 52 weeks)
Seizure freedom at 6 months comparing Levetiracetam versus older Antiepileptic Drugs
Time frame: Visit 1 to Visit 4 (approximately 26 weeks)
Seizure freedom at 12 months comparing Levetiracetam versus older Antiepileptic Drugs
Time frame: Visit 1 to Visit 5 (approximately 52 weeks)
Seizure freedom at 6 months comparing Levetiracetam versus older Antiepileptic Drugs based on based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release
Time frame: Visit 1 to Visit 4 (approximately 26 weeks)
Seizure freedom at 12 months comparing Levetiracetam versus older Antiepileptic Drugs based on based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release
Time frame: Visit 1 to Visit 5 (approximately 52 weeks)
Time to first seizure comparing Levetiracetam versus older Antiepileptic Drugs
Time frame: Visit 1 to End of Study (approximately 52 weeks)
Time to first seizure comparing Levetiracetam versus older Antiepileptic Drugs based on the subset of subjects whose best recommended treatment was Carbamazepine Controlled Release or Sodium Valproate Extended Release
Time frame: Visit 1 to End of Study (approximately 52 weeks)
Showing the first 100 of 231 sites across 24 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam